Comparison of three rapamycin dosing schedules in A/J Tsc2+/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors

Journal of Translational Medicine

Volumn 8, Issue , 2010, Pages

  Woodrum, Chelsey ^a   Nobil, Alison ^a   Dabora, Sandra L ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; BEVACIZUMAB; RAPAMYCIN; SUNITINIB; VINCRISTINE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; INDOLE DERIVATIVE; MONOCLONAL ANTIBODY; PYRROLE DERIVATIVE; TUBERIN; TUMOR SUPPRESSOR PROTEIN;

A J MOUSE; AGE DISTRIBUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; CYSTADENOMA; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG RESPONSE; FEMALE; KIDNEY CYSTADENOMA; MALE; MOUSE; NONHUMAN; SINGLE DRUG DOSE; SUBCUTANEOUS TISSUE TUMOR; SURVIVAL RATE; TUBEROUS SCLEROSIS; TUMOR GROWTH; ANIMAL; C57BL MOUSE; DISEASE MODEL; DRUG ADMINISTRATION; GENETICS; KIDNEY TUMOR; METABOLISM; NUDE MOUSE; PATHOLOGY; TRANSGENIC MOUSE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ASPARAGINASE; CYSTADENOMA; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; INDOLES; KIDNEY NEOPLASMS; MALE; MICE; MICE, INBRED C57BL; MICE, NUDE; MICE, TRANSGENIC; PYRROLES; SIROLIMUS; SURVIVAL RATE; TUBEROUS SCLEROSIS; TUMOR SUPPRESSOR PROTEINS; VINCRISTINE;

EID: 77949478751     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-8-14     Document Type: Article

References (74)

1. Gomez M, Sampson J, Whittemore V, . eds The tuberous sclerosis complex 1999, Oxford University Press: Oxford, England, Third, eds.
2. Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. N Engl J Med 2006, 355(13):1345-56. 10.1056/NEJMra055323, 17005952.
3. Dabora SL, Jozwiak S, Franz DN, Roberts PS, Nieto A, Chung J, Choy YS, Reeve MP, Thiele E, Egelhoff JC, Kasprzyk-Obara J, Domanska-Pakiela D, Kwiatkowski DJ. Mutational Analysis in a Cohort of 224 Tuberous Sclerosis Patients Indicates Increased Severity of TSC2, Compared with TSC1, Disease in Multiple Organs. Am J Hum Genet 2001, 68(1):64-80. 10.1086/316951, 1234935, 11112665.
4. Dabora SL, Roberts P, Nieto A, Perez R, Jozwiak S, Franz D, Bissler J, Thiele EA, Sims K, Kwiatkowski DJ. Association between a High-Expressing Interferon-gamma Allele and a Lower Frequency of Kidney Angiomyolipomas in TSC2 Patients. Am J Hum Genet 2002, 71(4):750-758. 10.1086/342718, 378533, 12192641.
5. Ewalt DH, Sheffield E, Sparagana SP, Delgado MR, Roach ES. Renal lesion growth in children with tuberous sclerosis complex. J Urol 1998, 160(1):141-5. 10.1016/S0022-5347(01)63072-6, 9628635.
6. Juvet SC, McCormack FX, Kwiatkowski DJ, Downey GP. Molecular pathogenesis of lymphangioleiomyomatosis: lessons learned from orphans. Am J Respir Cell Mol Biol 2007, 36(4):398-408. 10.1165/rcmb.2006-0372TR, 2176113, 17099139.
7. Carsillo T, Astrinidis A, Henske EP. Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci USA 2000, 97(11):6085-90. 10.1073/pnas.97.11.6085, 18562, 10823953.
8. Consortium ECTS. Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell 1993, 75(7):1305-15.
9. van Slegtenhorst M, de Hoogt R, Hermans C, Nellist M, Janssen B, Verhoef S, Lindhout D, Ouweland A, Halley D, Young J, Burley M, Jeremiah S, Woodward K, Nahmias J, Fox M, Ekong R, Osborne J, Wolfe J, Povey S, Snell RG, Cheadle JP, Jones AC, Tachataki M, Ravine D, Kwiatkowski DJ. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 1997, 277(5327):805-8. 10.1126/science.277.5327.805, 9242607.
10. Gao X, Pan D. TSC1 and TSC2 tumor suppressors antagonize insulin signaling in cell growth. Genes Dev 2001, 15(11):1383-92. 10.1101/gad.901101, 312704, 11390358.
11. Potter CJ, Huang H, Xu T. Drosophila Tsc1 functions with Tsc2 to antagonize insulin signaling in regulating cell growth, cell proliferation, and organ size. Cell 2001, 105(3):357-68. 10.1016/S0092-8674(01)00333-6, 11348592.
12. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006, 124(3):471-84. 10.1016/j.cell.2006.01.016, 16469695.
13. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008, 27(41):5497-510. 10.1038/onc.2008.245, 18794884.
14. Chiang GG, Abraham RT. Targeting the mTOR signaling network in cancer. Trends Mol Med 2007, 13(10):433-42. 10.1016/j.molmed.2007.08.001, 17905659.
15. Findlay GM, Harrington LS, Lamb RF. TSC1-2 tumour suppressor and regulation of mTOR signalling: linking cell growth and proliferation?. Curr Opin Genet Dev 2005, 15(1):69-76. 10.1016/j.gde.2004.11.002, 15661536.
16. Huang J, Manning BD. The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem J 2008, 412(2):179-90. 10.1042/BJ20080281, 2735030, 18466115.
17. Inoki K, Li Y, Xu T, Guan KL. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes & Development 2003, 17(15):1829-34.
18. Au KS, Williams AT, Roach ES, Batchelor L, Sparagana SP, Delgado MR, Wheless JW, Baumgartner JE, Roa BB, Wilson CM, Smith-Knuppel TK, Cheung MY, Whittemore VH, King TM, Northrup H. Genotype/phenotype correlation in 325 individuals referred for a diagnosis of tuberous sclerosis complex in the United States. Genet Med 2007, 9(2):88-100. 10.1097/GIM.0b013e31803068c7, 17304050.
19. Sancak O, Nellist M, Goedbloed M, Elfferich P, Wouters C, Maat-Kievit A, Zonnenberg B, Verhoef S, Halley D, Ouweland A. Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: genotype--phenotype correlations and comparison of diagnostic DNA techniques in Tuberous Sclerosis Complex. Eur J Hum Genet 2005, 13(6):731-41. 10.1038/sj.ejhg.5201402, 15798777.
20. Messina MP, Rauktys A, Lee L, Dabora SL. Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779. BMC Pharmacol 2007, 7:14. 10.1186/1471-2210-7-14, 2213639, 17986349.
21. Lee L, Sudentas P, Donohue B, Asrican K, Worku A, Walker V, Sun Y, Schmidt K, Albert MS, El-Hashemite N, Lader AS, Onda H, Zhang H, Kwiatkowski DJ, Dabora SL. Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models. Genes Chromosomes Cancer 2005, 42(3):213-27. 10.1002/gcc.20118, 15578690.
22. El-Hashemite N, Zhang H, Henske EP, Kwiatkowski DJ. Mutation in TSC2 and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma. Lancet 2003, 361(9366):1348-9. 10.1016/S0140-6736(03)13044-9, 12711473.
23. Chan JA, Zhang H, Roberts PS, Jozwiak S, Wieslawa G, Lewin-Kowalik J, Kotulska K, Kwiatkowski DJ. Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation. J Neuropathol Exp Neurol 2004, 63(12):1236-42.
24. Henske EP, Scheithauer BW, Short MP, Wollmann R, Nahmias J, Hornigold N, van Slegtenhorst M, Welsh CT, Kwiatkowski DJ. Allelic loss is frequent in tuberous sclerosis kidney lesions but rare in brain lesions. Am J Hum Genet 1996, 59(2):400-6. 1914733, 8755927.
25. Henske EP, Wessner LL, Golden J, Scheithauer BW, Vortmeyer AO, Zhuang Z, Klein-Szanto AJ, Kwiatkowski DJ, Yeung RS. Loss of tuberin in both subependymal giant cell astrocytomas and angiomyolipomas supports a two-hit model for the pathogenesis of tuberous sclerosis tumors. Am J Pathol 1997, 151(6):1639-47. 1858354, 9403714.
26. Hidalgo M, Rowinsky EK. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 2000, 19(56):6680-6. 10.1038/sj.onc.1204091, 11426655.
27. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, T O, Lustgarten S, Moore L, Motzer RJ. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007, 356(22):2271-81. 10.1056/NEJMoa066838, 17538086.
28. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008, 372(9637):449-56. 10.1016/S0140-6736(08)61039-9, 18653228.
29. Ikeda S, Mochizuki A, Sarker AH, Seki S. Identification of functional elements in the bidirectional promoter of the mouse Nthl1 and Tsc2 genes. Biochem Biophys Res Commun 2000, 273(3):1063-8. 10.1006/bbrc.2000.3071, 10891372.
30. Kenerson H, Dundon TA, Yeung RS. Effects of rapamycin in the Eker rat model of tuberous sclerosis complex. Pediatr Res 2005, 57(1):67-75. 10.1203/01.PDR.0000147727.78571.07, 15557109.
31. Lee L, Sudentas P, Dabora SL. Combination of a rapamycin analog (CCI-779) and interferon-gamma is more effective than single agents in treating a mouse model of tuberous sclerosis complex. Genes Chromosomes Cancer 2006, 45(10):933-44. 10.1002/gcc.20357, 16845661.
32. Franz DN, Leonard J, Tudor C, Chuck G, Care M, Sethuraman G, Dinopoulos A, Thomas G, Crone KR. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol 2006, 59(3):490-8. 10.1002/ana.20784, 16453317.
33. Davies DM, Johnson SR, Tattersfield AE, Kingswood JC, Cox JA, McCartney DL, Doyle T, Elmslie F, Saggar A, de Vries PJ, Sampson JR. Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis. N Engl J Med 2008, 358(2):200-3. 10.1056/NEJMc072500, 18184971.
34. Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, Schmithorst VJ, Laor T, Brody AS, Bean J, Salisbury S, Franz DN. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 2008, 358(2):140-51. 10.1056/NEJMoa063564, 18184959.
35. Avruch J, Hara K, Lin Y, Liu M, Long X, Ortiz-Vega S, Yonezawa K. Insulin and amino-acid regulation of mTOR signaling and kinase activity through the Rheb GTPase. Oncogene 2006, 25(48):6361-72. 10.1038/sj.onc.1209882, 17041622.
36. Silverman LB, Gelber RD, Dalton VK, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin MA, Arkin S, Declerck L, Cohen HJ, Sallan SE. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood 2001, 97(5):1211-8. 10.1182/blood.V97.5.1211, 11222362.
37. Iiboshi Y, Papst PJ, Hunger SP, Terada N. L-Asparaginase inhibits the rapamycin-targeted signaling pathway. Biochem Biophys Res Commun 1999, 260(2):534-9. 10.1006/bbrc.1999.0920, 10403802.
38. Reinert RB, Oberle LM, Wek SA, Bunpo P, Wang XP, Mileva I, Goodwin LO, Aldrich CJ, Durden DL, McNurlan MA, Wek RC, Anthony TG. Role of glutamine depletion in directing tissue-specific nutrient stress responses to L-asparaginase. J Biol Chem 2006, 281(42):31222-33. 10.1074/jbc.M604511200, 16931516.
39. Arbiser JL, Brat D, Hunter S, J D, Henske EP, Arbiser ZK, Bai X, Goldberg G, Cohen C, Weiss SW. Tuberous sclerosis-associated lesions of the kidney, brain, and skin are angiogenic neoplasms. J Am Acad Dermatol 2002, 46(3):376-80. 10.1067/mjd.2002.120530, 11862172.
40. Brugarolas JB, Vazquez F, Reddy A, Sellers WR, Kaelin WG. TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell 2003, 4(2):147-58. 10.1016/S1535-6108(03)00187-9, 12957289.
41. Seyama K, Kumasaka T, Souma S, Sato T, Kurihara M, Mitani K, Tominaga S, Fukuchi Y. Vascular endothelial growth factor-D is increased in serum of patients with lymphangioleiomyomatosis. Lymphat Res Biol 2006, 4(3):143-52. 10.1089/lrb.2006.4.143, 17034294.
42. Young LR, Inoue Y, McCormack FX. Diagnostic potential of serum VEGF-D for lymphangioleiomyomatosis. N Engl J Med 2008, 358(2):199-200. 10.1056/NEJMc0707517, 18184970.
43. Glasgow CG, Avila NA, Lin JP, Stylianou MP, Moss J. Serum vascular endothelial growth factor-D levels in patients with lymphangioleiomyomatosis reflect lymphatic involvement. Chest 2009, 135(5):1293-300. 10.1378/chest.08-1160, 19420197.
44. Adnane L, Trail PA, Taylor I, Wilhelm SM. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol 2006, 407:597-612. 10.1016/S0076-6879(05)07047-3, 16757355.
45. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004, 64(19):7099-109. 10.1158/0008-5472.CAN-04-1443, 15466206.
46. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356(2):125-34. 10.1056/NEJMoa060655, 17215530.
47. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M, Saltz LB. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006, 24(26):4293-300. 10.1200/JCO.2005.01.3441, 16908937.
48. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356(2):115-24. 10.1056/NEJMoa065044, 17215529.
49. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006, 368(9544):1329-38. 10.1016/S0140-6736(06)69446-4, 17046465.
50. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007, 357(26):2666-76. 10.1056/NEJMoa072113, 18160686.
51. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355(24):2542-50. 10.1056/NEJMoa061884, 17167137.
52. Nghiemphu PL, Liu W, Lee Y, Than T, Graham C, Lai A, Green RM, Pope WB, Liau LM, Mischel PS, Nelson SF, Elashoff R, Cloughesy TF. Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology 2009, 72(14):1217-22. 10.1212/01.wnl.0000345668.03039.90, 19349600.
53. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007, 25(12):1539-44. 10.1200/JCO.2006.09.6305, 17442997.
54. Wang Y, Fei D, Vanderlaan M, Song A. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 2004, 7(4):335-45. 10.1007/s10456-004-8272-2, 15886877.
55. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003, 349(5):427-34. 10.1056/NEJMoa021491, 2275324, 12890841.
56. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007, 370(9605):2103-11. 10.1016/S0140-6736(07)61904-7, 18156031.
57. Jiang X, Yeung RS. Regulation of microtubule-dependent protein transport by the TSC2/mammalian target of rapamycin pathway. Cancer Res 2006, 66(10):5258-69. 10.1158/0008-5472.CAN-05-4510, 16707451.
58. Mujagic H, Chen SS, Geist R, Occhipinti SJ, Conger BM, Smith CA, Schuette WH, Shackney SE. Effects of vincristine on cell survival, cell cycle progression, mitotic accumulation in asynchronously growing Sarcoma 180 cells. Cancer Res 1983, 43(8):3591-7.
59. Himes RH, Kersey RN, Heller-Bettinger I, Samson FE. Action of the vinca alkaloids vincristine, vinblastine, desacetyl vinblastine amide on microtubules in vitro. Cancer Res 1976, 36(10):3798-802.
60. Onda H, Lueck A, Marks PW, Warren HB, Kwiatkowski DJ. TSC2+/- mice develop tumors in multiple sites which express gelsolin and are influenced by genetic background. J Clin Invest 1999, 104(6):687-95. 10.1172/JCI7319, 408440, 10491404.
61. Lee N, Woodrum C, Nobil A, Rauktys A, Messina MP, Dabora SL. Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models. BMC Pharmacol 2009, 9:8. 10.1186/1471-2210-9-8, 2670829, 19368729.
62. de Bouard S, Herlin P, Christensen JG, Lemoisson E, Gauduchon P, Raymond E, Guillamo JS. Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma. Neuro Oncol 2007, 9(4):412-23. 10.1215/15228517-2007-024, 1994098, 17622648.
63. Huynh H, Teo CC, Soo KC. Bevacizumab and rapamycin inhibit tumor growth in peritoneal model of human ovarian cancer. Mol Cancer Ther 2007, 6(11):2959-66. 10.1158/1535-7163.MCT-07-0237, 18025280.
64. Liem NL, Papa RA, Milross CG, Schmid MA, Tajbakhsh M, Choi S, Ramirez CD, Rice AM, Haber M, Norris MD, MacKenzie KL, Lock RB. Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies. Blood 2004, 103(10):3905-14. 10.1182/blood-2003-08-2911, 14764536.
65. Rauktys A, Lee N, Lee L, Dabora SL. Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model. BMC Dermatol 2008, 8(1):1. 10.1186/1471-5945-8-1, 2266897, 18226258.
66. Doetschman T. Influence of genetic background on genetically engineered mouse phenotypes. Methods Mol Biol 2009, 530:423-33. full_text, 2805848, 19266333.
67. Meikle L, Pollizzi K, Egnor A, Kramvis I, Lane H, Sahin M, Kwiatkowski DJ. Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function. J Neurosci 2008, 28(21):5422-32. 10.1523/JNEUROSCI.0955-08.2008, 2633923, 18495876.
68. Ehninger D, Han S, Shilyansky C, Zhou Y, Li W, Kwiatkowski DJ, Ramesh V, Silva AJ. Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis. Nat Med 2008, 14(8):843-8. 10.1038/nm1788, 2664098, 18568033.
69. Zeng LH, Xu L, Gutmann DH, Wong M. Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Ann Neurol 2008, 63(4):444-53. 10.1002/ana.21331, 18389497.
70. Yu JJ, Robb VA, Morrison TA, Ariazi EA, Karbowniczek M, Astrinidis A, Wang C, Hernandez-Cuebas L, Seeholzer LF, Nicolas E, Hensley H, Jordan VC, Walker CL, Henske EP. Estrogen promotes the survival and pulmonary metastasis of tuberin-null cells. Proc Natl Acad Sci USA 2009, 106(8):2635-40. 10.1073/pnas.0810790106, 2637277,2637277, 19202070.
71. Pollizzi K, Malinowska-Kolodziej I, Stumm M, Lane H, Kwiatkowski D. Equivalent benefit of mTORC1 blockade and combined PI3K-mTOR blockade in a mouse model of tuberous sclerosis. Mol Cancer 2009, 8:38. 10.1186/1476-4598-8-38, 2702302, 19527517.
72. El-Hashemite N, Walker V, Kwiatkowski DJ. Estrogen enhances whereas tamoxifen retards development of Tsc mouse liver hemangioma: a tumor related to renal angiomyolipoma and pulmonary lymphangioleiomyomatosis. Cancer Res 2005, 65(6):2474-81. 10.1158/0008-5472.CAN-04-3840, 15781664.
73. Lenci I, Angelico M, Tisone G, Orlacchio A, Palmieri G, Pinci M, Bombardieri R, Curatolo P. Massive hepatic angiomyolipoma in a young woman with tuberous sclerosis complex: significant clinical improvement during tamoxifen treatment. J Hepatol 2008, 48(6):1026-9. 10.1016/j.jhep.2008.01.036, 18436329.
74. Finlay GA, Malhowski AJ, Polizzi K, Malinowska-Kolodziej I, Kwiatkowski DJ. Renal and liver tumors in Tsc2+/- mice, a model of tuberous sclerosis complex, do not respond to treatment with atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Mol Cancer Ther 2009, 8(7):1799-807. 10.1158/1535-7163.MCT-09-0055, 19584242.